Brian di Donato - 02 Jan 2024 Form 3 Insider Report for Immunocore Holdings plc (IMCR)

Role
Chief Financial Officer
Signature
/s/ Brian Di Donato
Issuer symbol
IMCR
Transactions as of
02 Jan 2024
Net transactions value
$0
Form type
3
Filing time
02 Jan 2024, 16:41:18 UTC
Next filing
21 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IMCR Ordinary Shares 19,230 02 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMCR Employee Share Option (Right to Buy) 02 Jan 2024 Ordinary Shares 56,250 $17.46 Direct F1
holding IMCR Employee Share Option (Right to Buy) 02 Jan 2024 Ordinary Shares 127,152 $26.00 Direct F2
holding IMCR Employee Share Option (Right to Buy) 02 Jan 2024 Ordinary Shares 67,977 $24.66 Direct F3
holding IMCR Employee Share Option (Right to Buy) 02 Jan 2024 Ordinary Shares 67,949 $64.53 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original option award was for 300,000 shares. 25% of the shares subject to the option award vested on July 1, 2021, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F2 The original option award was for 406,884 shares. 25% of the shares subject to the option award vested on February 4, 2022, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F3 The original option award was for 120,843 shares. 25% of the shares subject to the option award vested on February 16, 2023, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F4 25% of the shares subject to the option award shall vest on February 16, 2024, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney